Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
Authors:
- Natalia Yu. PshenichnayaNPNatalia Yu. Pshenichnaya
- Elena N. KarevaEKElena N. Kareva
- Irina A. LenevaILIrina A. Leneva
- Vilya A. BulgakovaVBVilya A. Bulgakova
- Irina E. KravchenkoIKIrina E. Kravchenko
- Irina V. NikolaevaINIrina V. Nikolaeva
- Antonina P. IvanovaAIAntonina P. Ivanova
- Larisa V. PuzyrevaLPLarisa V. Puzyreva
- Guzel M. KhasanovaGKGuzel M. Khasanova
- Svetlana N. OrlovaSOSvetlana N. Orlova
- Elena P. TikhonovaETElena P. Tikhonova
Open Access
- 15 November 2021
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (11) , 1306-1315
Abstract
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results. During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.Keywords
This publication has 21 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19Science, 2020
- Lopinavir/ritonavir is associated with pneumonia resolution in COVID‐19 patients with influenza coinfection: A retrospective matched‐pair cohort studyJournal of Medical Virology, 2020
- An empirical estimate of the infection fatality rate of COVID-19 from the first Italian outbreakmedRxiv, 2020
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)JAMA, 2020
- WHO Declares COVID-19 a Pandemic2020
- A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19bioRxiv, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected MiceCell Host & Microbe, 2016
- Prospective Observational Studies to Assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force ReportValue in Health, 2012